1. Pink Sheet
  2. >>Market Access

When It Comes To FTC M&A Review, The Times May Be A Changin'

 
• By Jessica Merrill

Spark signaled in an SEC filing that its merger with Roche could be delayed into 2020, fueling more speculation that FTC is increasing scrutiny over biopharma mergers.

Retro alarm clock on bright yellow background - Image

Pharma deal-making kicked into high gear in the first half of 2019, but getting big mergers through antitrust review by the US Federal Trade Commission may be a hard-fought battle. The FTC appears to be taking a tougher stance when it comes to reviewing the impact of biopharma deals on competition.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pricing Debate

More from Market Access